This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Schizophrenia  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Arch Gen Psychiatry. 2006;63:1074-1076.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Schizophrenia is among the most serious psychiatric illnesses, causing both personal suffering and impaired functioning. Almost 90% of people with this illness are not employed, and many rely on family assistance and public support to pay for their health care and daily living expenses. In 1990, the Americans With Disabilities Act sought to increase work opportunities and reduce disability. However, between 1994 and 2003, recipients of Social Security Administration disability benefits for schizophrenia increased by 35% from 400 000 to 550 000, double the rate of increase of cardiovascular disability and 3 times the 11% growth in the adult population (Pamela Mazerski, associate commissioner, Social Security Administration, written communication, 2004).

During these years, the dissemination of second-generation antipsychotic (SGA) medications has been the most hopeful development in the medical treatment of this illness. Dozens of studies have described reduced adverse effects, better compliance, and greater symptom reduction (especially for negative symptoms and . . . [Full Text of this Article]

AUTHOR INFORMATION
Robert A. Rosenheck, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

CUtLASS Confirms CATIE
Jim Mintz and Alex Kopelowicz
Arch Gen Psychiatry. 2007;64(8):978.
EXTRACT | FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
Chittaranjan Andrade and Saifuddin Kharawala
Arch Gen Psychiatry. 2007;64(8):978-979.
EXTRACT | FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia—Reply
Peter B. Jones, Thomas R. E. Barnes, Peter Elton, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Marwick, and Shôn Lewis
Arch Gen Psychiatry. 2007;64(8):979-980.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63(10):1069-1072.
EXTRACT | FULL TEXT  

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones, Thomas R. E. Barnes, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Markwick, and Shôn W. Lewis
Arch Gen Psychiatry. 2006;63(10):1079-1087.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CUtLASS Confirms CATIE
Mintz and Kopelowicz
Arch Gen Psychiatry 2007;64:978-978.
FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia Reply
Jones et al.
Arch Gen Psychiatry 2007;64:979-980.
FULL TEXT  

Outcomes of public concern in schizophrenia
Kooyman et al.
Br. J. Psychiatry 2007;191:s29-s36.
ABSTRACT | FULL TEXT  

Furor Therapeuticus: Benjamin Rush and the Philadelphia Yellow Fever Epidemic of 1793
Eisenberg
Am. J. Psychiatry 2007;164:552-555.
FULL TEXT  

Outcomes similar with first- and second-generation antipsychotics
Seidlinger
Am J Health Syst Pharm 2006;63:2172-2175.
FULL TEXT